Combo therapy trial achieves 94% remission rate for Hodgkin’s lymphoma
The trial was so successful the U.S.’s National Cancer Institute (NCI) ordered it be halted early so that the FDA could expedite approval of the therapy to treat stage 3 and 4 Hodgkin Lymphoma.
Combo therapy trial achieves 94% remission rate for Hodgkin’s lymphoma Read more